<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db00635 DrugCentral: prednisone Synonymous :1,2-dehydrocortisone | 1,4-pregnadiene-17α,21-diol-3,11,20-trione | 17,21-dihydroxypregna-1,4-diene-3,11,20-trione | dehydrocortisone | prednisona | prednisone | prednisonum 
Drug Sentece Context Table 1. Analysis of context sentence of prednisone gene in 44 abstracts.">

  
  <link rel="alternate" hreflang="en-us" href="https://bio-hub.github.io/drugpanel/prednisone/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://bio-hub.github.io/drugpanel/prednisone/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://bio-hub.github.io/drugpanel/prednisone/info/">
  <meta property="og:title" content="PREDNISONE | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db00635 DrugCentral: prednisone Synonymous :1,2-dehydrocortisone | 1,4-pregnadiene-17α,21-diol-3,11,20-trione | 17,21-dihydroxypregna-1,4-diene-3,11,20-trione | dehydrocortisone | prednisona | prednisone | prednisonum 
Drug Sentece Context Table 1. Analysis of context sentence of prednisone gene in 44 abstracts."><meta property="og:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>PREDNISONE | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">PREDNISONE</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db00635' target='_blank'>db00635</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=prednisone" target="_blank">prednisone</a> <br>
Synonymous :1,2-dehydrocortisone | 1,4-pregnadiene-17α,21-diol-3,11,20-trione | 17,21-dihydroxypregna-1,4-diene-3,11,20-trione | dehydrocortisone | prednisona | prednisone | prednisonum
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>prednisone</em> gene in 44 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32348046" target="_blank">32348046</a>
</td>
<td style="text-align:center;">
Leur arrêt n’est recommandé qu’en cas d’infection avérée à SARS-CoV-2, à l’exception de la prednisone, de l’hydroxychloroquine et de la sulfasalazine qui peuvent être poursuivis.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32351040" target="_blank">32351040</a>
</td>
<td style="text-align:center;">
Nine patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32382516" target="_blank">32382516</a>
</td>
<td style="text-align:center;">
She completed 5 days of hydroxychloroquine and 7 days of prednisone. […] It is unclear whether our institution’s empiric use of hydroxychloroquine and prednisone facilitated her recovery.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32400931" target="_blank">32400931</a>
</td>
<td style="text-align:center;">
His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32419721" target="_blank">32419721</a>
</td>
<td style="text-align:center;">
In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32436948" target="_blank">32436948</a>
</td>
<td style="text-align:center;">
We diagnosed SAT and the patient started prednisone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32471903" target="_blank">32471903</a>
</td>
<td style="text-align:center;">
In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32573882" target="_blank">32573882</a>
</td>
<td style="text-align:center;">
During hospitalization, calcineurin inhibitors and antimetabolites were held; prednisone was continued.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32583620" target="_blank">32583620</a>
</td>
<td style="text-align:center;">
All five patients were on immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus and three that were transplanted within the prior two months were additionally on prednisone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32646502" target="_blank">32646502</a>
</td>
<td style="text-align:center;">
The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission criteria. […] Patients will be followed-up by specialist physicians and Primary Health Care professionals. - Men and women. - Age between 18 and 75 years old. - Diagnosed SARS-CoV-2 infection, by PCR and/or IgM+ antibody test and/or antigen test. - Clinical diagnosis of lung involvement: (respiratory symptoms +/- pathological auscultation +/- O2 desaturation) - Chest X-ray with mild-moderate alterations or normal. - Patients who give their verbal informed consent in front of witnesses, which will be reflected in the patients’ medical records. - Oxygen desaturation below 93% or P02 &lt; 62. - Moderate-severe dyspnea or significant respiratory or general deterioration that makes admission advisable. - Chest X-ray with multifocal infiltrates. - Insulin-dependent diabetes with poor control or glycaemia in the emergency room test greater than 300 mg/ml (fasting or not). - Other significant comorbidities: Severe renal failure (creatinine clearance &lt; 30 mL/min); cirrhosis or chronic liver disease, poorly controlled hypertension. - Heart rhythm disturbances (including prolonged QT). - Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents); cancer. - Pregnant or breast-feeding women. - Patients under use of glucocorticoids for other diseases. - History of allergy or intolerance to any of the drugs in the study (prednisone, azithromycin or hydroxychloroquine). - Patients who took one or more of the study drugs in the 7 days prior to study inclusion. - Patients taking non-suppressible drugs with risk of QT prolongation or significant interactions. - Patients unwilling or unable to participate until study completion. - Participation in another study. […] Eligible patients will be randomized to receive standard outpatient treatment only (group 1) or standard outpatient treatment plus prednisone (group 2). - Group 1: paracetamol 1 g/8 h (on demand) + hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days. - Group 2: paracetamol 1 g/8 h (on demand) + hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days + prednisone 60 mg / 24 h for 3 days, 30 mg / 24 h for 3 days and 15 mg / 24 h for 3 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32676935" target="_blank">32676935</a>
</td>
<td style="text-align:center;">
All findings were consistent with SAT, and treatment with oral prednisone (25 mg/day as the starting dose, gradually tapered) was started.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32692733" target="_blank">32692733</a>
</td>
<td style="text-align:center;">
After finishing steroid treatment at home, the patient was readmitted with another episode of AIP complicated by development of acute necrotic collection and COVID-19 while taking a second course of high dose prednisone. […] The patient was continued on high dose prednisone, started on azathioprine and intravenous meropenem, and underwent CT guided percutaneous drainage.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32703929" target="_blank">32703929</a>
</td>
<td style="text-align:center;">
Kidney transplant patients encountered COVID-19 were maintained on tacrolimus (Tac, 92%), mycophenolate mofetil (MMF, 78.8%), and prednisone (Pred, 77%) and were manage by holding MMF in 79.1% of patients and holding Tac in 34.4% of patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32760619" target="_blank">32760619</a>
</td>
<td style="text-align:center;">
She was then treated with oral prednisone and subsequently discharged home after a prolonged course of eight days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32780854" target="_blank">32780854</a>
</td>
<td style="text-align:center;">
Symptoms disappeared a few days after commencement of treatment (prednisone in 3 patients and ibuprofen in 1).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32843098" target="_blank">32843098</a>
</td>
<td style="text-align:center;">
Patients under chronic treatment with glucocorticoids for other diseases (≥ 8 mg prednisone, or equivalent) Participation in another randomized clinical trial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32907638" target="_blank">32907638</a>
</td>
<td style="text-align:center;">
Documented interstitial pneumonia requiring admission and at least two of the following parameters: 1) Fever ≥ 37.8°C (tympanic) 2) IL-6 in serum ≥ 25 pg/mL (in the absence of a previous dose of prednisone or equivalent&gt; 1 mg / kg) or PCR&gt; 5mg/dL 3) Lymphocytes &lt;600 cells/mm3 4) Ferritin&gt; 300 μg/L that doubles in 24 hours 5) Ferritin&gt; 600 μg/L in the first determination and LDH&gt; 250 U/L 6) D-dimer (&gt; 1 mg/L) d.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32910433" target="_blank">32910433</a>
</td>
<td style="text-align:center;">
The patient was treated with a tapered prednisone dose with resolution of his diplopia but no change in Adie’s pupil.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32924059" target="_blank">32924059</a>
</td>
<td style="text-align:center;">
Intravenous gammaglobulin (78.1%) and methylprednisolone/prednisone(57.6%) were the most common therapeutic interventions ; immunomodulation was used in 24.3% of cases.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32943115" target="_blank">32943115</a>
</td>
<td style="text-align:center;">
This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1) b) subjects with solid organ transplantation c) subjects with bone marrow transplantation d) subjects under chemotherapy e) subjects with primary immunodeficiency f) subjects under treatment with any anti-cytokine therapy within the last year g) subjects under treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months h) Active solid or non-solid malignancy or lymphoma within the prior two years Direct involvement in the design or the execution of the BCG-DENMARK-COVID trial Intervention and comparator: Participants will be randomised to BCG vaccine (BCG-Denmark, AJ Vaccines, Copenhagen, Denmark) or placebo (saline).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32961675" target="_blank">32961675</a>
</td>
<td style="text-align:center;">
There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32971254" target="_blank">32971254</a>
</td>
<td style="text-align:center;">
The main exposure variable was corticosteroid therapy at a dose of ≥0.5 mg/kg of prednisone equivalents.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32974243" target="_blank">32974243</a>
</td>
<td style="text-align:center;">
He responded well to standard-dose prednisone treatment for nephrotic syndrome. […] At 1 week after starting the prednisone treatment, he went into clinical remission. […] The patient responded well to the standard-dose prednisone treatment that is typically used for new-onset nephrotic syndrome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32979013" target="_blank">32979013</a>
</td>
<td style="text-align:center;">
Patient received standard prednisone and tacrolimus-based immunosuppression without induction therapy following transplant.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32984404" target="_blank">32984404</a>
</td>
<td style="text-align:center;">
High-risk factors for COVID-19 complications, i.e., high-dose steroids (40 mg prednisone) and severe active disease, were present at admission.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32997868" target="_blank">32997868</a>
</td>
<td style="text-align:center;">
He was diagnosed with right peripheral facial palsy and was treated with prednisone 60 mg/24h with a tapering schedule.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33011038" target="_blank">33011038</a>
</td>
<td style="text-align:center;">
Oral prednisone therapy (5 mg) was initiated and the patient was discharged on a continued prednisone taper.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33041077" target="_blank">33041077</a>
</td>
<td style="text-align:center;">
The large proportion of infected individuals were minorities (Hispanic 65.9%, black 14.6%), on prednisone, tacrolimus, and mycophenolate mofetil (95.1%, 87.8%, and 87.8%, respectively), and had excellent allograft function (median 1.25 mg/dL).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048372" target="_blank">33048372</a>
</td>
<td style="text-align:center;">
We compared three groups based on immunosuppression regimen 7-12 months posttransplant: 1) tacrolimus (Tac)+mycophenolic acid (MPA)+prednisone (Pred) (referent group, 77.7%); 2) Tac+MPA+Pred+HCQ (16.5%); or 3) other immunosuppression+HCQ (5.7%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33067320" target="_blank">33067320</a>
</td>
<td style="text-align:center;">
Six patients (10%) had definite or probable COVID-19, but all recovered uneventfully, including two still on ICI and on low-to-moderate dose prednisone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33070314" target="_blank">33070314</a>
</td>
<td style="text-align:center;">
On follow-up, most patients presented almost complete resolution, although six patients required prednisone and antiaggregant drug treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33076856" target="_blank">33076856</a>
</td>
<td style="text-align:center;">
The upward trend did not begin until June 2020 and she took the tapering dose of prednisone under the instruction of the hematologist.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33100064" target="_blank">33100064</a>
</td>
<td style="text-align:center;">
A diuretic was administered, and prednisone was gradually reduced along with tacrolimus. […] Patients who develop COVID-19 after kidney transplantation are at risk of acute kidney injury, and their prednisone, immunosuppressant, and gamma globulin treatment must be adjusted according to their condition.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33106469" target="_blank">33106469</a>
</td>
<td style="text-align:center;">
Liver transplant patients infected with COVID-19 were maintained on Tac (79%), mycophenolate (MMF) (48.4%), and Prednisone (29.6%) and were managed by reducing MMF in 14.3% of patients and reducing Tac in 14.3% of patients; 28.6% of patients needed ICU admission, 13.6% of patients had died, and the reported general population COVID-19 mortality rate was 3.4%.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33137493" target="_blank">33137493</a>
</td>
<td style="text-align:center;">
In a large HMO in Brazil, our approach was to allow treating physicians to prescribe antiviral medications immediately at presentation, and prednisone starting on day-6 of symptoms to treat pulmonary inflammation. […] Use of hydroxychloroquine (HCQ), prednisone or both significantly reduced hospitalization risk by 50-60%. […] Similar magnitudes of reduced risk with HCQ and prednisone use were seen for mortality risk, though were not significant because of only 11 deaths among the 717 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33160408" target="_blank">33160408</a>
</td>
<td style="text-align:center;">
Offspring whose father filled at least one prescription of the following medications in the 3 months preceding conception were considered exposed: chloroquine, hydroxychloroquine, losartan, azithromycin, naproxen, dexamethasone and prednisone. […] For hydroxychloroquine and prednisone, exposure was limited (&lt; 300 offspring).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33194871" target="_blank">33194871</a>
</td>
<td style="text-align:center;">
He was treated with hydroxychloroquine, IV dexamethasone and ruxolitinib with rapid improvement of respiratory failure; 1 month after the second discharge, maintaining low-dose oral prednisone, lung consolidations were significantly reduced on control CT.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33219091" target="_blank">33219091</a>
</td>
<td style="text-align:center;">
Patients (n=48) with a variety of solid tumors received prednisone, methylprednisolone, or dexamethasone alone or in combination in doses ranging from 20 to 190 mg/24 hours (prednisone equivalent).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33274479" target="_blank">33274479</a>
</td>
<td style="text-align:center;">
All patients received clarithromycin, enoxaparin and methylprednisolone or prednisone up to 10 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33290446" target="_blank">33290446</a>
</td>
<td style="text-align:center;">
Nine patients were prescribed systemic prednisone and nasal irrigation with betamethasone, ambroxol and rinazine for 15 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33301283" target="_blank">33301283</a>
</td>
<td style="text-align:center;">
High-dose oral prednisone with taper, intratympanic dexamethasone. […] The patient was treated with two courses of high-dose oral prednisone with taper and a left intratympanic dexamethasone injection, resulting in near-resolution of vestibular symptoms, a fluctuating sensorineural hearing loss in the right ear, and a severe to profound mixed hearing loss in the left ear.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33301928" target="_blank">33301928</a>
</td>
<td style="text-align:center;">
We used routine care data from 51 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids at 0.8 mg/kg/day eq. prednisone (CTC group) versus standard of care (no-CTC group) among adults 18 to 80 years old with confirmed COVID-19 pneumonia requiring oxygen without mechanical ventilation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33331521" target="_blank">33331521</a>
</td>
<td style="text-align:center;">
We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. […] This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33335817" target="_blank">33335817</a>
</td>
<td style="text-align:center;">
Treatment started with antibiotics, prophylactic enoxaparin (40-mg subcutaneous once daily), methyl prednisone 60 mg BD and multivitamins.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33336061" target="_blank">33336061</a>
</td>
<td style="text-align:center;">
The patient used hydroxychloroquine and prednisone chronically to control the SLE. […] After infection of SARS-CoV-2, she was given higher dose of prednisone than before and the same dosage of hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33380371" target="_blank">33380371</a>
</td>
<td style="text-align:center;">
Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250mg of prednisone daily and use of equivalent doses greater than or equal to 250mg of prednisone daily. […] Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 [0.30-1.66]), treatment with glucocorticoids (≥250mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 [0.11-1.08]) and glucocorticoids treatment (≥250mg prednisone daily) versus patients with glucocorticoids doses &lt;250mg prednisone daily or without glucocorticoids treatment (OR: 0.30 [0.10-0.88]). […] The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250mg have a more favorable evolution (less mortality and less admission to ICU).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33410884" target="_blank">33410884</a>
</td>
<td style="text-align:center;">
Of these, 108 (5%) were classified as immunosuppressed before COVID-19, primarily with prednisone (&gt;7.5 mg/day), tacrolimus, or mycophenolate mofetil.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33451758" target="_blank">33451758</a>
</td>
<td style="text-align:center;">
Since the transplant, these 2 patients have received triple maintenance immunosuppressive therapy with oral tacrolimus, mycophenolate mofetil (MMF), and prednisone, and they have been regularly followed up at our hospital.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33457205" target="_blank">33457205</a>
</td>
<td style="text-align:center;">
The patient presented an improvement in skin lesions by the fifth day of prednisone therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33499887" target="_blank">33499887</a>
</td>
<td style="text-align:center;">
To evaluate the efficacy of early treatment with prednisone to decrease the progression of COVID-19 pneumonia. […] Experimental arm Prednisone 40 mg days 1 to 4. […] Then Prednisone 20 mg days 5 to 8.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33510992" target="_blank">33510992</a>
</td>
<td style="text-align:center;">
The patient was provided symptomatic treatment with prednisone and atenolol and had an uneventful recovery.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33529638" target="_blank">33529638</a>
</td>
<td style="text-align:center;">
The WM group received antiviral therapy (including abidor capsule 0.2 g po, tid; Lopinavir-Ritonavir tablets, 500 mg po, bid), antibiotics (such as cefoperazone, 2 g iv, bid; moxifloxacin hydrochloride tablets, 0.4 g po, qd) or corticosteroid therapy (such as methylprednisolone succinate sodium, 40mg, iv, 40 mg, qd; prednisone, 30 mg po, qd).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33532070" target="_blank">33532070</a>
</td>
<td style="text-align:center;">
Our protocol of treatment was based on early use of prednisone (25 mg in the morning and 12.5 mg in the afternoon) and low molecular weight heparin (4000 UI one or two times daily) initiated just after the positivity of molecular nasopharyngeal test (about 3-4 days as mean time after initiation of symptomatology and not after 7-8 days as suggested by other protocols) and oxygen therapy when necessary.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33546739" target="_blank">33546739</a>
</td>
<td style="text-align:center;">
In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33567251" target="_blank">33567251</a>
</td>
<td style="text-align:center;">
The patients were treated with a high dose of corticosteroids (prednisone 1 mg/kg PO), showing marked clinical improvement, and decreasing oxygen flow ratio demand.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33572634" target="_blank">33572634</a>
</td>
<td style="text-align:center;">
The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33585689" target="_blank">33585689</a>
</td>
<td style="text-align:center;">
Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250 mg of prednisone daily and use of equivalent doses greater than or equal to 250 mg of prednisone daily. […] Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 (0.30-1.66)), treatment with glucocorticoids (≥ 250 mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 (0.11-1.08)) and glucocorticoids treatment (≥ 250 mg prednisone daily) versus patients with glucocorticoids doses &lt;250 mg prednisone daily or without glucocorticoids treatment (OR: 0.30 (0.10-0.88)). […] The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250 mg have a more favorable evolution (less mortality and less admission to ICU).
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
